Literature DB >> 4364538

Epstein-Barr virus-associated membrane-reactive antibodies during long term survival Burkitt's lymphoma.

P Gunvén, G Klein, P Clifford, S Singh.   

Abstract

Antibodies to Epstein-Barr virus associated cell membrane antigens persisted or slowly decreased during prolonged uncomplicated survival of patients with Burkitt's lymphoma in remission. Serum was sampled from four patients within 6 months before recurrence occurring after the first year and preceded by remission during more than 6 months. Rapid and significant decreases of the antibodies before clinical recognition of the recurrences were found in three patients. The fourth patient had slowly increasing titers before relapse. Immune stimulant treatment during remission, with BCG (Bacille Calmette Guérin vaccine) or BCG + Bordetella pertussis, temporarily increased the antibody levels. Possible mechanisms for the observed titer changes before recurrence are discussed.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4364538      PMCID： PMC388241          DOI： 10.1073/pnas.71.4.1422

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  22 in total

1.  Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients.

Authors:  P Gunvén; G Klein; G Henle; W Henle; P Clifford
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

2.  EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.

Authors:  H zur Hausen; H Schulte-Holthausen; G Klein; W Henle; G Henle; P Clifford; L Santesson
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

3.  Antibodies to early Epstein-Barr virus-induced antigens in Burkitt's lymphoma.

Authors:  G Henle; W Henle; G Klein; P Gunven; P Clifford; R H Morrow; J L Ziegler
Journal:  J Natl Cancer Inst       Date:  1971-04       Impact factor: 13.506

4.  EB viral antigens in Burkitt tumor biopsies and early cultures.

Authors:  J S Nadkarni; J J Nadkarni; G Klein; W Henle; G Henle; P Clifford
Journal:  Int J Cancer       Date:  1970-07-15       Impact factor: 7.396

5.  Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures.

Authors:  G Klein; P Clifford; E Klein; R T Smith; J Minowada; F M Kourilsky; J H Burchenal
Journal:  J Natl Cancer Inst       Date:  1967-11       Impact factor: 13.506

6.  Treatment of Burkitt's lymphoma.

Authors:  P Clifford; U Gripenberg; E Klein; E M Fenyo; G Manolov
Journal:  Lancet       Date:  1968-08-31       Impact factor: 79.321

7.  Direct membrane immunofluorescence reaction of Burkitt's lymphoma cells in culture.

Authors:  G Goldstein; G Klein; G Pearson; P Clifford
Journal:  Cancer Res       Date:  1969-04       Impact factor: 12.701

8.  EBV-associated serological patterns in a Burkitt lymphoma patient during regression and recurrence.

Authors:  G Klein; P Clifford; G Henle; W Henle; G Geering; L J Old
Journal:  Int J Cancer       Date:  1969-07-15       Impact factor: 7.396

9.  Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups.

Authors:  G Henle; W Henle; P Clifford; V Diehl; G W Kafuko; B G Kirya; G Klein; R H Morrow; G M Munube; P Pike; P M Tukei; J L Ziegler
Journal:  J Natl Cancer Inst       Date:  1969-11       Impact factor: 13.506

10.  Long-term survival of patients with Burkitt's lymphoma: an assessment of treatment and other factors which may relate to survival.

Authors:  P Clifford; S Singh; J Stjernswärd; G Klein
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.